At this rate I envisage we’ll dose cohort one by Q1 2023 and may get an early efficacy announcement…
Ann: First Patient Recruited to ACCENT Trial in Pancreatic Cancer, page-57
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
13.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $37.01M | |||
| Open | High | Low | Value | Volume |
| 13.0¢ | 13.5¢ | 13.0¢ | $16.79K | 124.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 534 | 13.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 14.0¢ | 7478 | 7 |
View Market Depth
| Last trade - 14.11pm 16/08/2024 (20 minute delay) ? |
| ATX (ASX) Chart |